Display options
Cite
Fritah S, Muller A, Jiang W, et al. Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. Cancers (Basel). 2020;12(9)doi: 10.3390/cancers12092583.
Fritah, S., Muller, A., Jiang, W., Mitra, R., Sarmini, M., Dieterle, M., Golebiewska, A., Ye, T., Van Dyck, E., Herold-Mende, C., Zhao, Z., Azuaje, F., & Niclou, S. P. (2020). Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. Cancers, 12(9), . https://doi.org/10.3390/cancers12092583
Fritah, Sabrina, et al. "Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma." Cancers vol. 12,9 (2020). doi: https://doi.org/10.3390/cancers12092583
Fritah S, Muller A, Jiang W, Mitra R, Sarmini M, Dieterle M, Golebiewska A, Ye T, Van Dyck E, Herold-Mende C, Zhao Z, Azuaje F, Niclou SP. Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. Cancers (Basel). 2020 Sep 10;12(9). doi: 10.3390/cancers12092583. PMID: 32927769; PMCID: PMC7563839.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Sep 10;12(9). doi: 10.3390/cancers12092583.

Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma.

Cancers

Sabrina Fritah, Arnaud Muller, Wei Jiang, Ramkrishna Mitra, Mohamad Sarmini, Monika Dieterle, Anna Golebiewska, Tao Ye, Eric Van Dyck, Christel Herold-Mende, Zhongming Zhao, Francisco Azuaje, Simone P Niclou

Affiliations

  1. NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
  2. Quantitative Biology Unit, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
  3. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37203, USA.
  4. Faculty of Science, Technology and Medicine, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg.
  5. Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique, UMR7104, Institut National de la Santé et de la Recherche Médicale, U964, Université de Strasbourg, 67404 Illkirch, France.
  6. DNA Repair and Chemoresistance, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
  7. Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, 69120 Heidelberg, Germany.
  8. School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  9. Department of Biomedicine, University of Bergen, N-5009 Bergen, Norway.

PMID: 32927769 PMCID: PMC7563839 DOI: 10.3390/cancers12092583

Abstract

Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma (GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet, their contribution to the transcriptional response to drugs is less understood. Here, we performed RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for regulatory mechanisms, we integrated thousands of molecular associations stored in public databases to generate a background "RNA interactome". Our systems-level analysis uncovered a coordinated program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs, miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM. The computational modeling used to identify regulatory circuits underlying drug response and prioritizing gene candidates for functional validation is applicable to other datasets.

Keywords: chemoresistance; glioblastoma; lncRNA; regulatory circuit; temozolomide; transcriptome

References

  1. BMC Med Genomics. 2018 Dec 31;11(Suppl 6):120 - PubMed
  2. Gene. 2019 May 15;696:1-9 - PubMed
  3. Neurology. 2011 Mar 29;76(13):1126-34 - PubMed
  4. Neurosci Lett. 2016 Aug 15;628:161-6 - PubMed
  5. J Cell Mol Med. 2018 Oct;22(10):4611-4616 - PubMed
  6. Cancer Chemother Pharmacol. 2009 Oct;64(5):1053-8 - PubMed
  7. Clin Chim Acta. 2015 Apr 15;444:280-8 - PubMed
  8. Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7 - PubMed
  9. Cell Death Dis. 2018 Aug 6;9(8):841 - PubMed
  10. Cancer Lett. 2015 Apr 1;359(1):75-86 - PubMed
  11. Anticancer Agents Med Chem. 2014 Jan;14(1):9-17 - PubMed
  12. Cell Death Dis. 2019 Mar 13;10(3):246 - PubMed
  13. J Transl Med. 2015 Feb 26;13:74 - PubMed
  14. Genes Dev. 2011 Sep 15;25(18):1915-27 - PubMed
  15. Nat Commun. 2019 Apr 16;10(1):1787 - PubMed
  16. Curr Mol Pharmacol. 2012 Jan;5(1):102-14 - PubMed
  17. Trends Biochem Sci. 2014 Apr;39(4):170-82 - PubMed
  18. Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102 - PubMed
  19. Acta Neuropathol. 2012 Oct;124(4):547-60 - PubMed
  20. Cancers (Basel). 2019 Jun 30;11(7): - PubMed
  21. Nucleic Acids Res. 2013 Jul;41(Web Server issue):W77-83 - PubMed
  22. RNA. 2014 Nov;20(11):1655-65 - PubMed
  23. Oncogene. 2007 Jan 11;26(2):186-97 - PubMed
  24. Cell. 2016 Jan 14;164(1-2):69-80 - PubMed
  25. Cancer Res. 2008 Jul 15;68(14):5706-15 - PubMed
  26. Mutat Res Rev Mutat Res. 2016 Jul-Sep;769:19-35 - PubMed
  27. N Engl J Med. 2005 Mar 10;352(10):997-1003 - PubMed
  28. Nature. 2012 Sep 6;489(7414):101-8 - PubMed
  29. J Biomol Screen. 2004 Jun;9(4):273-85 - PubMed
  30. Glia. 2011 Dec;59(12):1974-86 - PubMed
  31. Bioinformatics. 2012 Aug 1;28(15):2062-3 - PubMed
  32. Int J Clin Exp Med. 2015 Oct 15;8(10):17110-6 - PubMed
  33. Pharmacol Ther. 2018 Apr;184:13-41 - PubMed
  34. Oncotarget. 2016 May 31;7(22):31955-71 - PubMed
  35. Genome Res. 2014 May;24(5):869-84 - PubMed
  36. Annu Rev Genet. 2015;49:673-95 - PubMed
  37. Drug Discov Today. 2015 Jul;20(7):899-905 - PubMed
  38. Mol Med. 2011 Jan-Feb;17(1-2):103-12 - PubMed
  39. Mol Cancer Ther. 2013 Nov;12(11):2529-40 - PubMed
  40. Exp Neurol. 2000 Jan;161(1):67-84 - PubMed
  41. Nat Struct Mol Biol. 2013 Jul;20(7):908-13 - PubMed
  42. Nature. 2012 Sep 6;489(7414):57-74 - PubMed
  43. Int J Mol Sci. 2020 Mar 05;21(5): - PubMed
  44. Cell. 2011 Aug 5;146(3):353-8 - PubMed
  45. DNA Repair (Amst). 2007 Aug 1;6(8):1079-99 - PubMed
  46. Cancer Res. 2001 Mar 1;61(5):1957-63 - PubMed
  47. Genes Dev. 2009 Dec 15;23(24):2839-49 - PubMed
  48. Nucleic Acids Res. 2013 Jan;41(Database issue):D246-51 - PubMed
  49. Cell Rep. 2016 Jun 14;15(11):2500-9 - PubMed
  50. Nucleic Acids Res. 2013 Jan;41(Database issue):D177-87 - PubMed
  51. J Cell Biochem. 2017 Dec;118(12):4897-4904 - PubMed
  52. Clin Cancer Res. 2010 May 15;16(10):2715-28 - PubMed
  53. Science. 2010 Aug 6;329(5992):689-93 - PubMed
  54. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8326-31 - PubMed
  55. Oncotarget. 2017 Nov 28;8(67):110785-110796 - PubMed
  56. Mol Cancer. 2013 Oct 29;12(1):131 - PubMed
  57. Cancer Res. 2014 Mar 15;74(6):1651-60 - PubMed
  58. Nucleic Acids Res. 2013 Apr 1;41(6):e74 - PubMed
  59. Cell Biosci. 2018 Mar 22;8:23 - PubMed
  60. Oncotarget. 2016 Jul 5;7(27):41737-41747 - PubMed
  61. J Biotechnol. 2010 Jul 1;148(1):3-15 - PubMed
  62. Oncotarget. 2014 Nov 30;5(22):10976-96 - PubMed
  63. Nat Rev Neurol. 2010 Jan;6(1):39-51 - PubMed
  64. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  65. PLoS Comput Biol. 2012;8(7):e1002488 - PubMed

Publication Types

Grant support